ICLUSIG, discovered by Ariad (acquired by Takeda in 2017), an oral tyrosine kinase inhibitor, targets BCR-ABL, an abnormal kinase expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ICLUSIG was launched in Japan in 2016.

Busulfex is a conditioning agent prior to bone marrow transplantation in blood cancer. It has been accepted globally as a standard treatment to support medical transplantation.

Samsca is an Otsuka-discovered aquaretic with a novel mechanism of action that promotes excretion from the body of water only without affecting the excretion of electrolytes. It does this by inhibiting the antidiuretic hormone vasopressin. In Japan, it was approved for edema from heart failure (accumulation of fluid) in 2010 and edema for cirrhotic patients in 2013. In 2014 Samsca was approved in Japan as the first-in-the-world treatment of autosomal dominant polycystic kidney disease (ADPKD), and additional approvals have been received in geographies including North America and the EU member states. Currently, Samsca / JINARC / JYNARQUE is approved for several indications in over 40 countries.

SAMTASU is a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in the human body following administration. Tolvaptan, discovered by Otsuka, is a novel compound that is as an antagonist of the vasopressin V₂-receptor. In Japan, SAMTASU was approved for edema from heart failure (accumulation of fluid) in 2022.

Pletaal, discovered by Otsuka, inhibits platelet aggregation and has peripheral vasodilator effects. In Japan it was launched in 1988 for the treatment of symptoms associated with chronic arterial obstruction and was also approved in 2003 for prevention of recurrent cerebral infarction. In 2010, Pletaal OD tablets were released in Japan.

Otsuka-discovered Mucosta has an action that protects the gastric mucosa in addition to suppressing free radicals and inflammation in the stomach. It was launched in Japan in 1990 and is now sold in multiple countries. It is widely used as a drug to control gastric mucosa injury triggered by various causes such as use of painkillers and the effects of Helicobacter pylori.

DELTYBA, discovered by Otsuka, is one of the first new anti-tuberculosis (TB) agents in nearly 40 years. It has a new mechanism of action with antimicrobial effect by inhibition of the production of mycolic acids, which form the cell wall of TB bacteria. As a treatment for multidrug-resistant TB, DELTYBA was approved in Europe in 2014. In Japan, it was also launched in 2014. In 2015 it was listed in the WHO Essential Medicines List. Currently, DELTYBA is available in over 120 countries.

Mucosta ophthalmic suspension is a novel dry eye treatment with action that repairs corneal and conjunctival damage by promoting the production of mucin. It was launched in Japan in 2012 as a disposable, unit-dose formulation.

Mikeluna combination ophthalmic solution is an once-daily eye drop containing a combination of the Otsuka-developed β-blocker cartelol hydrochloride (Mikelan LA) and the prostaglandin analogue latanoprost. It launched in Japan in 2017.

Moizerto, discovered by Otsuka, is a non-steroidal, topical phosphodiesterase type-4 inhibitor (commonly called a PDE4 inhibitor). PDE4 inhibitors improve the symptoms of atopic dermatitis such as red and itchy skin, through suppression of the production of chemical mediators such as pro-inflammatory cytokines and through other anti-inflammatory effects. It was launched in 2022 as the first topical PDE4 inhibitor approved in Japan for the treatment of atopic dermatitis.

UBIT, discovered by Otsuka, is a diagnostic agent that measures ¹³C-Urea in the breath to detect the presence of Helicobacter pylori in the stomach.